What the New Medicare Law Says
Title I of the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003 (MMA), enacted on
December 8, 2003, creates the new prescription discount drug card
and transitional assistance program.
Drug Discount Cards
The
law requires the Department of Health and Human Services to
implement a new program of Medicare-approved prescription drug
discount cards. Senior citizens who participate in this voluntary
program will receive access to discounts negotiated by the private
card sponsor they select. HHS anticipates that those who use the
drug discount cards will see savings of 10 percent to 25 percent on
their prescription drug purchases, although some drug-card sponsors
believe they can offer even larger discounts, especially for
direct-mail purchases and generics.
Congress specified that the discount card
program would take effect no later than six months after the date
of enactment of the legislation. On December 10, 2003--two days
after the legislation was signed--HHS published an "interim final
rule" for the Medicare Prescription Drug Discount Card Program to
notify prospective sponsors about the rules of participation.
Seniors will be able to start using the Medicare-endorsed drug
discount cards on June 1, 2004.
The
cards are intended primarily for beneficiaries, regardless of
income, who currently do not have outpatient prescription drug
insurance. Medicare beneficiaries are eligible for the drug
discount card program if they are enrolled in Parts A or B and as
long as they are not receiving outpatient drug benefits through
Medicaid.
Transitional Cash Assistance
A
key part of the program is a cash subsidy of $600 per year for
eligible lower-income beneficiaries to use in purchasing
prescription drugs. The funds will be provided through the
particular drug discount card program selected by the beneficiary.
The provision was designed to provide immediate help for certain
seniors and disabled people on Medicare until the new Medicare drug
benefit is implemented on January 1, 2006.
Individuals whose incomes are less than
135 percent of the poverty rate may qualify for the cash subsidy.
For singles, this means those making less than $12,569 per year;
for married couples, it means those making less than $16,862 per
year. Medicare
beneficiaries who are also eligible to receive assistance for
prescription drugs through Medicaid, TRICARE for Life, or an employer group
health plan may not receive the cash subsidy.
For
those eligible for this transitional assistance, the federal
government will pay the annual enrollment fee for the drug discount
cards and also will provide a subsidy on the drug discount card of
$600 each year in 2004 and 2005.
The
new law establishes two categories of recipients for whom
assistance will be offered:
- Those with incomes below 100 percent of
the poverty rate would be responsible for prescription drug
co-payments of 5 percent.
- Those with incomes of 100 percent to 135
percent of the poverty rate would have 10 percent co-payments.
Legislators decided that even low-income
seniors should pay at least something for their drugs so that they
would appreciate the value of the benefit. Therefore, after
selecting the drug discount card program of their choice, seniors
will pay 5 percent or 10 percent of the costs of their medicines,
depending upon their income category. The balance, or the remaining
95 percent or 90 percent of the discounted drug costs, will be
subtracted from their $600 allowance.
Medicare beneficiaries currently without
prescription drug insurance would pay about $1,400, on average, to
purchase their drugs in 2004, absent the prescription drug card
program. HHS concludes that the $600 subsidy, coupled with the drug
discounts, will be of substantial help to them.
Those eligible for transitional assistance
will receive the full $600 subsidy for 2004 even though the program
does not begin until mid-year. Significantly, any balance left over
from the $600 subsidy at the end of 2004 may be added to the 2005
allocation. However, the legislation stipulates that both the
temporary discount card program and the $600 subsidies will end in
2006, to be replaced by the full Medicare Prescription Drug Benefit
program. At that time, seniors can enroll either in one of the new
subsidized Medicare Part D Prescription Drug Plans or in a Medicare
Advantage plan to receive drug coverage.
Additional Assistance Through Private
Programs
Most
pharmaceutical companies plan to continue their existing discount
programs, which provide drugs to low- and moderate-income seniors
at lower prices, in conjunction with the transitional Medicare
program. Many companies are working on initiatives that will
enhance the value of the Medicare drug card to beneficiaries. For
example:
- Merck announced in February that it will
provide its medicines free of charge for low-income Medicare
beneficiaries who exhaust their $600 transitional assistance
allowance (although there may be a fee to the pharmacist to
dispense the drugs).
- Eli Lilly announced in January that it
would make discounts available through its LillyAnswers program to
lower- and moderate-income seniors using Medicare-endorsed drug
cards. The Lilly program allows seniors with incomes below 200
percent of poverty without prescription drug coverage to pay a flat
fee of $12 for a 30-day supply of any Lilly medication.
- Pfizer will continue its Share Card
program, which charges $15 a month to fill any prescription for
single Medicare beneficiaries who do not have drug insurance and
who have incomes below $18,000, and for couples without drug
insurance making less than $24,000. Pfizer will also partner with a
Medicare drug card sponsor.
- Other programs, such as the
GlaxoSmithKline Orange Card and the Together Rx card offered by an
affiliation of eight major drug companies, will continue to offer
discounts of up to 40 percent on their medications to qualifying
seniors.
Senior citizens may find that they can
save money by enrolling in both the Medicare drug discount card
program and one or more card programs offered by private vendors.
While seniors can participate in only one Medicare-approved program
at a time, there is no limit on their participation with other,
non-Medicare-approved drug discount programs. Seniors who qualify
for the $600 transitional assistance subsidy must sign up for a
Medicare-approved drug discount card in order to receive this
money.
Some
of these private programs may provide savings superior to the
Medicare-approved drug cards. For example, once their $600 subsidy
is exhausted, seniors may decide to transfer back to those
pharmaceutical company drug card programs that operate
independently of the Medicare-approved drug cards. Getting a
month's supply of Pfizer's Lipitor for $15, for example, is likely
to be a better deal than the discounted price seniors would get
through a Medicare-approved drug discount card. The $15 fee
basically covers dispensing fees and program administration costs,
with little or no payment for the drug itself. Therefore, charges
from the private pharmaceutical company plans are likely to be
lower than those from the Medicare discount card prices.
Enrollment
Beneficiaries will first select the
discount card program of their choice when enrollment begins on May
3, 2004. Enrollment is voluntary. As mentioned earlier, the
legislation specifies that beneficiaries may enroll in only one
Medicare-approved drug discount card program at a time.
The
legislation details the application processes for drug card
programs, including a standard enrollment form for beneficiaries,
and allows the sponsor to collect annual enrollment fees of up to
$30. The beneficiary will fill out the enrollment form with basic
information about his or her Medicare and Medicaid status.
If
the beneficiary wants to participate in the $600 subsidy program,
he or she will be required to submit information about income and
other retirement and health benefits. HHS will verify information
on beneficiary eligibility for the subsidy.
Medicare Administrator Mark McClellan says
his agency is taking action to make it easier for low-income
Americans to receive the $600 benefit. Some states will be able to
automatically enroll low-income seniors in the Transitional
Assistance Program, provided their laws allow state officials to
sign enrollment forms on seniors' behalf. Medicare also will
provide a standard enrollment form for the program on its Web site,
eliminating the need for dozens of different low-income application
forms for each drug plan.
Beneficiaries generally can switch to
another approved plan only during the open enrollment period
between November 15 and December 31, 2004.
Card Sponsors
Card
sponsors can be pharmacy benefit management companies, wholesale
and retail pharmacies, insurers, Medicare Advantage health plans,
and partnerships of the above. In March, HHS approved 71 Medicare
drug discount card applications. Of these, 28 were general card
sponsors who will offer their discounts to beneficiaries enrolled
in fee-for-service Medicare, either on a national or regional
basis. Another 43 sponsors represent Medicare Advantage health
plans that will offer the discount cards to their members.
The
major pharmacy benefit managers (PBMs), such as Advance PCS Health,
LP, Caremark Advantage, Inc., Express Scripts, Inc., WellPoint
Pharmacy Management, and Medco Health Solutions, Inc., will
participate, along with major health plans such as Aetna Health
Management, LLC, Humana Insurance Company, and United Healthcare
Insurance Company.
CMS
rejected 29 applications, demonstrating its prudence in protecting
Medicare beneficiaries. The applications were rejected primarily
because the companies seeking approval did not have adequate
financial resources, because they did not offer drug discounts in
all 209 therapeutic categories, or because their networks did not
meet CMS's criteria for operating in a sufficient number of
pharmacies.
Discount card sponsors must have
sufficient participation by bricks-and-mortar pharmacies in the
regions where they are offering the cards, in addition to offering
mail-order services to enrollees. Express Scripts said in February
that it already had signed up more than 40,000 pharmacies
nationwide to participate in its card program. Seniors in a given
area must have a choice of at least two discount card programs,
offered by different sponsors. With at least 17 drug cards approved
nationally, that legislative criterion was easily met.
Other service area specifications
stipulate that 90 percent of Medicare beneficiaries living in urban
areas must have a participating pharmacy within two miles of their
homes (five miles in suburban areas) and that 70 percent of those
living in rural areas must have a participating pharmacy within 15
miles of where they live.
Drug
card plans are required to cover at least one drug in each of 209
therapeutic categories. At least 55 percent of these categories
must have a generic available, and pharmacists are required to
notify beneficiaries if a lower-priced generic is available for the
prescription they are seeking to fill. Card sponsors will be able
to add or drop drugs from their formularies, and sponsors will be
able to change the discounts available on individual
pharmaceuticals. Price increases will be limited, however, ensuring
that beneficiaries will face only those price increases prevailing
in the market or that result from increases in the card plan's cost
of operation.
Critics have charged that there will be
mass confusion for seniors trying to sort through the offers,
claims, and prices of so many discount cards. Indeed, it will be a
challenge for companies to market their cards to customers and to
distinguish their plans from their competitors' in such a short
time frame once enrollment begins in May.
The
CMS is planning to help by establishing a hotline (1-800-MEDICARE)
and a Web site with information about the cards, including
comparative pricing information on each drug for each card. The Web
site will be updated weekly.
Impact of the Drug Card Provisions
Controversy continues to swirl around the
new Medicare law, particularly with regard to the structure of the
permanent prescription drug benefit, including the "doughnut
hole," whether
government should "negotiate" drug prices, and questions about
potential participation in 2006 both by seniors and by stand-alone
prescription drug plans. This contrasts with the early acceptance
and interest in the transitional drug discount card and the $600
subsidy.
Many
companies that have applied to participate see the $600 subsidy as
an attractive lure to enroll Medicare beneficiaries in their
programs. These sponsors plan to market their cards actively and,
in the process, educate seniors about this new assistance
program.
The
temporary discount card program may well turn out to be so popular
that Congress could decide to extend it beyond 2005. As both the
government and private sector gain more experience with the
program, it could serve as a model for a larger Medicare drug
benefit program. The $600 subsidy is essentially a defined
contribution that gives seniors an incentive to get the best value
for their money. Further, by participating in the discount card
program, the money will go further than it would if seniors were
paying the full retail price--as many without drug coverage
currently do.
Reducing Prices and Maintaining Broad
Access to Pharmaceuticals
The
drug discount card program and the broader Part D benefit that
becomes available in 2006 are designed to promote competition among
private drug-only plans and comprehensive health plans (such as
HMOs and PPOs) that offer a drug benefit to their members. The
private plans will have an incentive to negotiate low prices from
pharmaceutical manufacturers, which would be passed on to
beneficiaries in the form of lower premiums and out-of-pocket
costs. In addition to making their benefits financially attractive
to potential enrollees, card sponsors and drug plans will offer
customer conveniences, including a broad retail network of
pharmacies, mail order service, telephone consultations, and the
like.
The
size of the discounts available to seniors who enroll in the
Medicare drug discount card program depends on the ability of the
plan sponsors to shift consumer demand from one product in a drug
class to another. Pharmacy benefit managers have been successful in
negotiating low drug prices for private insurance plans by using
multi-tiered formularies that require lower copayments for
preferred drugs and generics. A similar kind of financial incentive
is possible for the Medicare discount card program, with sponsors
of the discount cards offering larger discounts where they have
negotiated better prices.
Using Private Competition to Deliver the
Medicare Drug Benefit
The
role of private competition has been a major point of contention in
Congress. Critics of a competitive system argue that it could place
beneficiaries at a disadvantage if plans change their formularies
or discounts after the open enrollment period. Critics also assert
that the government should exploit its market power and negotiate
drug prices directly with manufacturers, and that drugs should be
imported from Canada to keep prices low for everyone.
Bait and
Switch
First, let us consider the concern that plans might bait
and switch--advertising prices that are too good to be true and
then raising prices after seniors are locked into the plan. HHS
anticipated this possibility and built safeguards into the
regulations. It will monitor price changes and allow them only
within a limited range that reflects increases in a drug's average
wholesale price or changes in the card sponsor's cost of
operation.
Another requirement is that discounts,
rebates, or other price concessions from pharmaceutical
manufacturers or pharmacies must be accounted for in any proposed
price increase to beneficiaries. In addition, HHS must be notified
if the sponsor proposes to drop a drug from its formulary. HHS will
then post the prices and formulary changes on its Web site.
Card
sponsors clearly recognize that arbitrary price increases or
formulary changes would be highly unpopular with beneficiaries and
federal overseers alike. Card plans that do not meet reasonable
consumer expectations will lose enrollment and could face expulsion
from the program.
The
risk of bait-and-switch tactics would be greater if drug card
sponsors had only a short-term interest in the Medicare program, so
that the loss of market share after the first year would be of
little consequence. But most, if not all, prospective sponsors of
the Medicare discount card are well-established firms with
reputations to protect, and the majority of them are considering
continued involvement with Medicare through the Part D benefit. For
such sponsors, bait-and-switch practices would be bad business,
placing them at a competitive disadvantage.
The Impact of
Private Negotiations on Drug Prices
There is heated controversy over whether the government
should be allowed to "negotiate" prices with pharmaceutical
companies since, the argument goes, the government would be able to
obtain lower drug prices than private firms. But government doesn't
negotiate. It is a
monopsony purchaser that dictates prices because it controls such a
large customer base: Seniors consume about half of all prescription
drugs sold in the United States.
Government would surely dictate prices
that would shrink payments to pharmaceutical companies--payments
that fund their investment in research and development, estimated
to be more than $800 million for every new drug that comes to the
market. The result
would be less money, a less hospitable business climate for
research, and fewer new drugs.
Further, Congressional Budget Office
Director Douglas Holtz-Eakin wrote a letter on January 23, 2004, to
Senate Majority Leader Bill Frist (R-TN) concerning the provision
in the Medicare law that prohibits the government from negotiating
prices with drug companies. The CBO concluded that:
striking that provision would have a
negligible effect on federal spending ... because CBO estimates
that substantial savings will be obtained by the private [drug]
plans and that the [HHS] Secretary would not be able to negotiate
prices that further reduced federal spending to a significant
degree.
Drug Importation
from Canada
Some critics of the new Medicare law argue that it would
be better and cheaper simply to allow seniors to import drugs from
Canada, where price controls prevail. The temporary drug card
program provides a much safer and legal alternative for seniors
than importing drugs from Canada or other countries. The Food and
Drug Administration has found numerous safety problems involving
prescription drugs sent to customers who order over the Internet
from the United States.
If
wholesale importation were permitted, retail prices paid in the
U.S. would decline only modestly because manufacturers would limit
sales to Canadian wholesalers, and middlemen would eat up much of
any price differences that arose. If importation occurred on a
large scale, supply disruptions in other countries could threaten
the worldwide distribution of pharmaceuticals.
Using the legal route of privately
negotiated drug discounts from reputable, government-approved
firms, with the added benefit of the $600 subsidy, is a much safer
alternative for seniors.
How to Improve the Medicare Drug Card
Provisions
Every Congress for years to come will be
forced to address Medicare and, particularly, the prescription drug
benefit. Senate Minority Leader Tom Daschle (D-SD) and others
already have introduced legislation that would significantly amend
the MMA. For example, they want to permit U.S. residents to
purchase medications from Canada; to allow the federal government
to "negotiate" lower drug prices; to fill the "doughnut hole" in
the new Medicare drug benefit; and to restrict or eliminate the
pilot test in which private health plans would compete against
traditional, fee-for-service Medicare in six areas of the country
beginning in 2010. Such proposals would be ineffective, costly, and
damaging to health care innovation, and would shorten the time
frame within which Medicare's financial crisis can be solved.
Conservatives will continue to be on the
defensive against these and other initiatives unless they have
ideas of their own to propose. They should start by calling for the
temporary drug card program to be made permanent. They should also
consider improving the benefit available in a permanent drug card
program and allowing Medicare Advantage plans greater flexibility
in offering a drug benefit to enrollees.
Proposal #1: Make the Drug Card Permanent
for Beneficiaries Who Want It
The
drug discount card program, and particularly its $600 subsidy for
lower-income seniors, should not expire at the end of 2005 but
should be allowed to continue. The funded drug card provides an
excellent model for delivery of the drug benefit. Providing part of the
benefit through a cash subsidy creates a defined contribution that
gives government certainty over at least some of its program costs
and rewards seniors for making prudent drug purchasing
decisions.
Early experience with consumer-directed
health benefit programs has demonstrated that consumers are more
careful in their spending on health care needs when they are
purchasing medical goods and services from a dollar-denominated
account, particularly if they are allowed to roll over any savings
to subsequent years. The rollover provision for the
temporary drug card could be a particularly good incentive if the
card program were to continue: Instead of the use-it-or-lose-it
benefit structure under current Medicare, seniors could roll over
unspent balances in their $600 account, giving them the opportunity
to conserve resources for the future.
However, because the program is temporary,
there is little incentive for seniors to save and every incentive
to make sure they drain every dollar from the account. This occurs
every December when workers, who have put pre-tax wages into a
Section 125 flexible spending account, purchase designer
prescription sunglasses or whatever other items they don't really
need in order to make sure they don't just lose the money. Congress
could avoid repeating this mistake by making the funded drug card a
permanent program and allowing rollover of the balance in a
senior's account from year to year.
One
reason such a large number of companies applied to participate in
the drug discount and transitional assistance program is that they
want to establish a customer base for the full drug benefit in
2006. They will have made a significant investment in creating
their temporary drug card programs and, if they find that the
funded drug card is appealing to consumers, should have the option
of continuing to offer the permanent benefit based upon a similar
structure.
Proposal #2: Improve the Permanent Drug
Card Option
The
Medicare drug discount card program offers a limited benefit from
which low-income seniors derive the greatest benefit and that was
intended to serve only as a temporary bridge to a more generous
benefit in 2006. If the drug discount program were to be made
permanent, it would not be attractive compared to the more generous
Part D benefit. But improvements could be made that would make a
permanent funded discount drug card program a realistic option for
more beneficiaries.
It
is reasonable to give seniors the choice of a subsidized discount
card account. The added resources available in 2006 could allow the
account to be funded more generously and to be coupled with private
catastrophic insurance.
The
subsidy could be increased above the current $600 limit and could
be extended to middle-income seniors who are not currently eligible
for any subsidy in the discount card program. Seniors at higher
income levels also could be allowed to participate, possibly with
more modest subsidies to their card accounts than would be provided
to low- and moderate-income seniors, but with the provision that
they could make their own tax-deductible contributions to the
accounts.
The
funded drug card also could be coupled with private catastrophic
drug insurance to make sure that seniors are protected against
large drug expenses--something the temporary program lacks. To
avoid attracting only the healthiest seniors into the permanent
drug card program, subsidies could be adjusted for risk, and high
risks could be pooled across all private plans (including Part D
plans).
Seniors should be given the opportunity to
continue to participate in this funded discount card program if
they prefer it to the permanent Medicare drug benefit program.
Proposal #3: Integrate the Drug Card Into
the Medicare Advantage Program
Beginning in 2006, the new Medicare
Advantage health plans can incorporate the permanent prescription
drug benefit created by the legislation into their benefit
structures. The legislation gives the new plans limited leeway,
however, in how they structure the drug benefit. Although they may
want to build a benefit on the model of the temporary drug discount
and assistance program, the legislation as currently drafted does
not provide the needed flexibility. Congress could fix this.
Seniors who prefer a funded drug card should be able to have it as
an integral part of their overall health plan.
It
is important to bring drug and medical benefits into the same plan.
When health plans and drug plans are separate, there can be an
incentive to push costs onto the other payer, potentially
compromising patient care. An integrated plan can weigh the full
costs and benefits of different treatment strategies rather than
focusing on only part of the treatment. That reduces the chances
that treatment decisions will be biased by the way benefits are
financed.
Conclusion
Congress has provided a good start on a
properly structured drug benefit through its transitional drug card
program with funding for certain low-income beneficiaries. Drug
discounts will be privately negotiated by competing drug plans, and
seniors will have a wide range of plans from which to choose, each
offering different menus of drugs.
Establishing a fixed contribution on the
drug discount card enables government to know its costs while the
prices--and savings--on drugs are visible to seniors. Experience
with consumer-directed health plans shows that participants are
likely to be more cost conscious when they are purchasing drugs
from a cash account. Consumers also are more likely to consult with
their doctors about how they can get the best value from their drug
spending.
If
the transitional drug discount program were improved and made
permanent, seniors would have the power to save for future drug
needs and would have more control over spending to get the drugs
they need--whether generic or brand-name.
Involving consumers in their own health
care spending decisions will be the next revolution in health care
reform in the United States. By structuring the drug benefit so
that consumers direct their own spending, Congress could, for once,
keep Medicare abreast of the times and give seniors the power and
resources to shape the pharmaceutical marketplace around their
needs, both today and in the future.
Grace-Marie Turner is President of the Galen
Institute, and Joseph R. Antos, Ph.D., is Wilson H. Taylor Scholar
in Health Care and Retirement Policy at the American Enterprise
Institute.